Scarica l'app Stockscreener
12.44
2.28%
-0.29
Dopo l'orario di chiusura:
12.38
-0.06
-0.48%
Precedente Chiudi:
$12.73
Aprire:
$12.72
Volume 24 ore:
48,866
Relative Volume:
3.79
Capitalizzazione di mercato:
$63.48M
Reddito:
-
Utile/perdita netta:
$-12.49M
Rapporto P/E:
-4.1959
EPS:
-2.9648
Flusso di cassa netto:
$-5.93M
1 W Prestazione:
+2.13%
1M Prestazione:
+9.80%
6M Prestazione:
+16.37%
1 anno Prestazione:
-19.53%
Intervallo 1D:
$12.10
$12.72
Intervallo di 1 settimana:
$11.71
$12.98
Portata 52W:
$8.4801
$16.93
Mink Therapeutics Inc Stock (INKT) Company Profile
Nome
Mink Therapeutics Inc
Settore
Industria
Telefono
212-994-8250
Indirizzo
149 FIFTH AVENUE, NEW YORK
Compare INKT vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
12.44 | 62.15M | 0 | -12.49M | -5.93M | -2.9648 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-07-14 | Downgrade | William Blair | Outperform → Mkt Perform |
Mink Therapeutics Inc Borsa (INKT) Ultime notizie
MiNK Therapeutics Selected for ARPA-H Initiative to Develop Room-Temperature Cell Therapy - Oncodaily
MiNK’s iNKT platform selected for $87M ARPA-H program By Investing.com - Investing.com South Africa
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy - Investing News Network
MiNK’s iNKT platform selected for $87M ARPA-H program - Investing.com
MiNK Therapeutics’ agenT-797 Selected for ARPA-H BoSS Program to Advance Room-Temperature Cell Therapy Storage - Quiver Quantitative
Mink Therapeutics, Inc. Announces Selection of Clinical-Stage Agent-797 Inkt Platform for Arpa-H-Funded Initiative to Advance Room-Temperature Cell Therapy - marketscreener.com
(INKT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Live MiNK Therapeutics, Inc. (INKT) Technical Analysis - Traders Union
Jennifer S. Buell to Discuss Clinical Development in LATAM – MiNK Therapeutics - Oncodaily
Understanding Momentum Shifts in (INKT) - Stock Traders Daily
Why (INKT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
INKT Q2 2026 Earnings: Wider-than-Expected Loss Reflects Ongoing Pre-Revenue Pipeline InvestmentEPS Surprise History - careplusvn.com
MiNK Therapeutics (INKT) insider reports stock trades - Stock Titan
Insider at MiNK Therapeutics (NASDAQ: INKT) reports stock transactions - Stock Titan
Mink Therapeutics, Inc. (INKT) Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
MiNK Therapeutics (INKT) Drops 6.1% to $11.06 on Biotech Sector WeaknessLong Setup Ideas - dars.gov.et
MiNK (INKT) Results at a Glance: EPS Does Not Reach the Reported Estimate in the Reported Period; After Earnings: Shares Move Lower 3.11% in Latest TradingPre-Announcement Alert - dars.gov.et
MiNK Therapeutics Earnings Call Highlights ARDS Push - TipRanks
MiNK (INKT) Results Versus Estimates: EPS Does Not Reach the Reported Estimate for the Current Session; Trading Move: The Market Price Declines 3.11% for the Current SessionDividend Increase Stocks - careplusvn.com
MiNK (INKT) Move: Finishes 4.99% Higher at $12.20 in the Current Update; Next Test: the $11.59 to $12.81 Range Remains in Focus in the Latest SessionCalendar Spread Trade - siam.in
MiNK (INKT) Move: Moves 0.15% Up to $11.37 for the Current Session; Price Setup: Support at $10.80 and Resistance at $11.94 Frame the Range at the CloseAI Trade Signals - vinanet.vn
MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript - AOL.ca
Q3 EPS Estimate for MiNK Therapeutics Boosted by Analyst - MarketBeat
MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript - Sahm
H.C. Wainwright Maintains MiNK Therapeutics(INKT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
MiNK Therapeutics (NASDAQ:INKT) Stock Rating Lowered by Zacks Research - MarketBeat
INKT|Mink Therapeutics Inc|Price:11.680| - TradingKey
MiNK Therapeutics (NASDAQ:INKT) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
MiNK Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
MiNK Therapeutics (INKT) Slides 5.17% as Biotech Stock Tests Key Support at $10.45AAII Neutral - vinanet.vn
MiNK Therapeutics, Inc. (INKT) Presents at 2026 Military Health System Research SymposiumSlideshow - Seeking Alpha
MiNK Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
META_TITLE_QUOTE - Yahoo Finance
MiNK Therapeutics Q2 Earnings Call Highlights - MarketBeat
MiNK Therapeutics Q2 Results: Net loss narrows to $3.1M, cash at $8.8M - scanx.trade
INKT: Advanced phase II ARDS trial and global access for agenT-797, with stable financials - TradingView
MiNK Therapeutics (INKT.US) will release its earnings report after market close on August 13. - 富途牛牛
Earnings call transcript: MiNK Therapeutics narrows Q2 2026 loss as trial advances - Investing.com
Transcript : MiNK Therapeutics, Inc., Q2 2026 Earnings Call, Aug 13, 2026 - marketscreener.com
INKT: Phase II trial for agenT-797 in ARDS shows early promise; global access and financial discipline maintained - TradingView
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury - Investing News Network
Form 8K Mink Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
MiNK Therapeutics reports Phase 2 trial data for agenT-797 By Investing.com - Investing.com Australia
MiNK Therapeutics reports Phase 2 trial data for agenT-797 - Investing.com
MiNK Reports $3.1 Million Second-Quarter Loss and Phase 2 ARDS Update - Quiver Quantitative
MiNK Therapeutics Q2 loss narrows on expense discipline - TradingView
MiNK Therapeutics Reports Second Quarter 2026 Financial - GlobeNewswire
Mink Therapeutics Inc (INKT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mink Therapeutics Inc expected to post a loss of 60 cents a shareEarnings Preview - TradingView
MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium - The Manila Times
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates - Investing News Network
Mink Therapeutics Inc Azioni (INKT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Mink Therapeutics Inc Azioni (INKT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ryan Barbara | Director |
Mar 10 '26 |
Sale |
15.40 |
1,300 |
20,017 |
20,406 |
| Ryan Barbara | Director |
Mar 09 '26 |
Sale |
10.17 |
200 |
2,034 |
21,706 |
| Ryan Barbara | Director |
Feb 27 '26 |
Sale |
10.86 |
400 |
4,343 |
22,006 |
| Ryan Barbara | Director |
Mar 02 '26 |
Sale |
10.83 |
100 |
1,083 |
21,906 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):